Browsing byAuthorShah, K

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 14 of 14
Issue DateTitleAuthor(s)
2018-06-01Comparing the UK EQ-5D-3L and English EQ-5D-5L Value SetsMulhern, B; Feng, Y; Shah, K; Janssen, MF; Herdman, M; van Hout, B; Devlin, N
2018-06-01Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets (PharmacoEconomics, (2018), 36, 6, (699-713), 10.1007/s40273-018-0628-3)Mulhern, B; Feng, Y; Shah, K; Janssen, MF; Herdman, M; van Hout, B; Devlin, N
2022-10Criteria for developing, assessing and selecting candidate EQ-5D bolt-ons.Mulhern, BJ; Sampson, C; Haywood, P; Addo, R; Page, K; Mott, D; Shah, K; Janssen, MF; Herdman, M
2019-07-01Cultural Values: Can They Explain Differences in Health Utilities between Countries?Roudijk, B; Donders, ART; Stalmeier, PFM; Luo, N; Viney, R; Andrade, MV; Gudex, C; de Pouvourville, G; Greiner, W; Scalone, L; Tsuchiya, A; Golicki, D; Ferreira, P; Prevolnik-Rupel, V; Badia, X; Hsieh, CL; Jelsma, J; Santos, M; Xie, F; Purba, F; Ikeda, S; Shiroiwa, T; Stolk, E; Jo, MW; Ramos-Goñi, JM; Augustovski, F; Rey-Ares, L; Devlin, N; Shah, K; Pattanaphesaj, J; Tongsiri, S
2019-01-01Development Of EQ-5D-5L bolt-ons for cognition and visionHaywood, P; Sampson, C; Addo, R; Herdman, M; Janssen, B; Mulhern, B; Page, K; Reardon, O; Rodes Sanchez, M; Schneider, J; Shah, K; Thetford, C
2015-05-01DIRECTLY ELICITING PERSONAL UTILITY FUNCTIONS: A NEW WAY TO VALUE HEALTH-RELATED QUALITY OF LIFEShah, K; Devlin, N; Mulhern, B; van Hout, B
2016-01-01An empirical study of two alternative comparators for use in time trade-off studiesShah, K; Mulhern, B; Longworth, L; Janssen, MF
2020The EQ-5D-5L Value Set for England: Response to the “Quality Assurance”van Hout, B; Mulhern, B; Feng, Y; Shah, K; Devlin, N
2023-10Feasibility of Microlearning for Improving the Self-Efficacy of Cancer Patients Managing Side Effects of Chemotherapy.Janssen, A; Shah, K; Rabbets, M; Nagrial, A; Pene, C; Zachulski, C; Phillips, JL; Harnett, P; Shaw, T
2018-04-01How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?Mulhern, B; Norman, R; Shah, K; Bansback, N; Longworth, L; Viney, R
2022-01-01Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes.Halloran, PF; Madill-Thomsen, K; Aliabadi-Zuckermann, AZ; Cadeiras, M; Crespo-Leiro, MG; Depasquale, EC; Deng, M; Gökler, J; Kim, DH; Kobashigawa, J; Macdonald, P; Potena, L; Shah, K; Stehlik, J; Zuckermann, A
2023-11-30Molecular states associated with dysfunction and graft loss in heart transplants.Halloran, PF; Madill-Thomsen, K; Mackova, M; Aliabadi-Zuckermann, AZ; Cadeiras, M; Crespo-Leiro, MG; Depasquale, EC; Deng, M; Gökler, J; Hall, SA; Kim, DH; Kobashigawa, J; Macdonald, P; Potena, L; Shah, K; Stehlik, J; Zuckermann, A; Reeve, J
2021-04-01New Molecular Classification of Rejection in Heart Transplant Biopsies Reveals Relatively Little Three Year Graft Loss in Antibody-Mediated RejectionHalloran, PF; Madill-Thomsen, K; Mackova, M; Aliabadi-Zuckermann, A; Cadeiras, M; Crespo-Leiro, M; Depasquale, E; Deng, M; Goekler, J; Kim, DH; Kobashigawa, J; Parkes, M; Macdonald, P; Potena, L; Shah, K; Stehlik, J; Zuckermann, A
2018-05-01Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experimentCole, A; Shah, K; Mulhern, B; Feng, Y; Devlin, N